Annalise.ai, a leader in AI-powered medical imaging solutions, has received 510(k) clearance from the U.S. FDA for its software to triage and notify healthcare providers about obstructive hydrocephalus (OHCP) on non-contrast brain CT scans.
This software has also been granted FDA Breakthrough Device Designation, making it the first radiology triage device to receive such status under the FDA's program. The FDA's Breakthrough Devices Program aims to provide quick access to medical devices that improve the treatment or diagnosis of life-threatening conditions, ensuring they meet safety and effectiveness standards.
Annalise.ai's advanced solution can passively and actively notify healthcare professionals of suspected OHCP cases identified on unenhanced head CT scans. With this clearance, Annalise.ai now has a total of ten FDA-cleared findings, five for chest X-rays (CXR) and five for head CT scans (CTB), solidifying its position as a comprehensive provider of FDA-cleared AI triage solutions in the U.S.
Obstructive hydrocephalus is a potentially life-threatening condition involving the accumulation of cerebrospinal fluid in the cranial vault, leading to increased intracranial pressure if untreated.
This FDA designation underscores Annalise.ai's commitment to improving patient access to advanced medical solutions addressing critical healthcare needs. CEO Lakshmi Gudapakkam emphasised their dedication to revolutionising medical imaging and enhancing diagnostic capabilities for conditions like obstructive hydrocephalus.
Click here to read the original news story.